A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Cancers
- Markman, Ben (Primary Chief Investigator (PCI))
- Day, Daphne (Chief Investigator (CI))
- Body, Amy (Partner Investigator (PI))
Project: Research